Zepatier
Generic name: Elbasvir And Grazoprevir
Drug class:
Antiviral combinations
Usage of Zepatier
Zepatier contains a combination of elbasvir and grazoprevir. Elbasvir and grazoprevir are antiviral medicines that prevent hepatitis C (HCV) from multiplying in your body.
Zepatier is used to treat chronic hepatitis C (HCV) in adults and children 12 years of age and older or weighing at least 66 pounds (30 kilograms). This medicine is sometimes given together with another drug called ribavirin.
Zepatier treats specific genotypes (1 or 4) of HCV infection, and only in certain people. Use only the medications prescribed for you. Do not share your medicine with other people.
Zepatier is sometimes used in people who also have HIV. This medicine is not a treatment for HIV or AIDS.
Zepatier side effects
Get emergency medical help if you have signs of an allergic reaction to Zepatier: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
In rare cases, Zepatier may cause serious liver injury. Tell your doctor right away if you have symptoms such as:
If you also take ribavirin, tell your doctor if you have symptoms of low red blood cells (anemia):
Common Zepatier side effects may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Zepatier
You should not use Zepatier if you are allergic to elbasvir or grazoprevir, or if you have:
When Zepatier with ribavirin: To make sure all medicines are safe for you, tell your doctor about all your medical conditions, and if you are pregnant or breastfeeding.
Many drugs can interact and cause dangerous effects. Some drugs should not be used together with elbasvir and grazoprevir.
Your doctor may change your treatment plan if you also use:
Tell your doctor if you have ever had:
Zepatier is sometimes used in combination with ribavirin. Both men and women using ribavirin should use effective birth control to prevent pregnancy. Ribavirin can cause birth defects, miscarriage, or death to an unborn baby if the mother or father is using this medicine.
You should not take ribavirin if you are pregnant, or if you are a man and your sex partner is pregnant. Use effective birth control to prevent pregnancy. Keep using birth control for at least 6 months after your last dose of ribavirin.
Tell your doctor right away if a pregnancy occurs while either the mother or the father is using ribavirin.
It may not be safe to breastfeed while using this medicine. Ask your doctor about any risk.
Zepatier is not approved for use by anyone younger than 18 years old.
Relate drugs
- AccessPak for HIV PEP Basic
- AccessPak for HIV PEP Expanded with Kaletra
- AccessPak for HIV PEP Expanded with Viracept
- Atazanavir and cobicistat
- Atripla
- Cobicistat and darunavir
- Cobicistat, darunavir, emtricitabine, and tenofovir
- Cobicistat, elvitegravir, emtricitabine, and tenofovir
- Combivir
- Complera
- Abacavir and lamivudine
- Abacavir, dolutegravir, and lamivudine
- Abacavir, lamivudine, and zidovudine
- Bictegravir, emtricitabine, and tenofovir
- Bictegravir, emtricitabine, and tenofovir alafenamide
- Biktarvy
- Cabenuva
- Cabotegravir and rilpivirine
- Casirivimab and imdevimab
- Cilgavimab and tixagevimab
- Cimduo
- Darunavir and cobicistat
- Darunavir, cobicistat, emtricitabine, and tenofovir alafenamide
- Dasabuvir, ombitasvir, paritaprevir, and ritonavir
- Delstrigo
- Descovy
- Descovy Blister Pack
- Dolutegravir and lamivudine
- Dolutegravir and rilpivirine
- Doravirine, lamivudine, and tenofovir
- Dovato
- Efavirenz, emtricitabine, and tenofovir
- Efavirenz, lamivudine, and tenofovir
- Elbasvir and grazoprevir
- Elvitegravir, cobicistat, emtricitabine, and tenofovir
- Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide
- Emtricitabine and tenofovir
- Emtricitabine and tenofovir alafenamide
- Emtricitabine, lopinavir, ritonavir, and tenofovir
- Emtricitabine, nelfinavir, and tenofovir
- Emtricitabine, rilpivirine, and tenofovir
- Emtricitabine, rilpivirine, and tenofovir alafenamide
- Epclusa
- Epzicom
- Evotaz
- Evusheld
- Genvoya
- Glecaprevir and pibrentasvir
- Harvoni
- Juluca
- Lamivudine and tenofovir
- Lamivudine and zidovudine
- Ledipasvir and sofosbuvir
- Mavyret
- Nirmatrelvir and ritonavir
- Odefsey
- Ombitasvir, paritaprevir, and ritonavir
- Ombitasvir, paritaprevir, ritonavir and dasabuvir
- Paxlovid
- Prezcobix
- Regen-Cov
- Sofosbuvir and Velpatasvir
- Sofosbuvir, velpatasvir, and voxilaprevir
- Stribild
- Symfi
- Symfi Lo
- Symtuza
- Technivie
- Temixys
- Triumeq
- Triumeq PD
- Trizivir
- Truvada
- Viekira
- Viekira Pak
- Viekira XR
- Vosevi
- Zepatier
How to use Zepatier
Usual Adult Dose for Chronic Hepatitis C:
1 tablet orally once a day Recommended Regimen and Duration of Therapy: -Genotype 1a, therapy-naive or peginterferon alfa/ribavirin-experienced without baseline nonstructural protein 5A (NS5A) polymorphisms: Elbasvir-grazoprevir for 12 weeks -Genotype 1a, therapy-naive or peginterferon alfa/ribavirin-experienced with baseline NS5A polymorphisms: Elbasvir-grazoprevir plus ribavirin for 16 weeks -Genotype 1b, therapy-naive or peginterferon alfa/ribavirin-experienced: Elbasvir-grazoprevir for 12 weeks -Genotype 1a or 1b, peginterferon alfa/ribavirin/HCV protease inhibitor-experienced: Elbasvir-grazoprevir plus ribavirin for 12 weeks -Genotype 4, therapy-naive: Elbasvir-grazoprevir for 12 weeks -Genotype 4, peginterferon alfa/ribavirin-experienced: Elbasvir-grazoprevir plus ribavirin for 16 weeks Comments: -This drug should be used with ribavirin in certain patient populations. -Hepatic laboratory testing recommended prior to and during therapy. -Peginterferon alfa/ribavirin-experienced: Patients who have failed therapy with peginterferon alfa plus ribavirin -Baseline NS5A polymorphisms: NS5A resistance-associated polymorphisms at amino acid positions 28, 30, 31, or 93. -Peginterferon alfa/ribavirin/HCV protease inhibitor-experienced: Patients who have failed therapy with peginterferon alfa plus ribavirin plus HCV NS3/4A protease inhibitor (e.g., boceprevir, simeprevir, telaprevir) -Optimal regimen and duration of therapy not established for peginterferon alfa/ribavirin/HCV protease inhibitor-experienced genotype 1a-infected patients with at least 1 baseline NS5A resistance-associated polymorphism at positions 28, 30, 31, and 93. -The manufacturer product information for ribavirin tablets should be consulted regarding dosing and dose adjustments (if applicable). Use: For the treatment of chronic HCV genotype 1 or 4 infection
Usual Pediatric Dose for Chronic Hepatitis C:
12 years and older OR weighing at least 30 kg: 1 tablet orally once a day Recommended Regimen and Duration of Therapy: -Genotype 1a, therapy-naive or peginterferon alfa/ribavirin-experienced without baseline NS5A polymorphisms: Elbasvir-grazoprevir for 12 weeks -Genotype 1a, therapy-naive or peginterferon alfa/ribavirin-experienced with baseline NS5A polymorphisms: Elbasvir-grazoprevir plus ribavirin for 16 weeks -Genotype 1b, therapy-naive or peginterferon alfa/ribavirin-experienced: Elbasvir-grazoprevir for 12 weeks -Genotype 1a or 1b, peginterferon alfa/ribavirin/HCV protease inhibitor-experienced: Elbasvir-grazoprevir plus ribavirin for 12 weeks -Genotype 4, therapy-naive: Elbasvir-grazoprevir for 12 weeks -Genotype 4, peginterferon alfa/ribavirin-experienced: Elbasvir-grazoprevir plus ribavirin for 16 weeks Comments: -This drug should be used with ribavirin in certain patient populations. -Hepatic laboratory testing recommended prior to and during therapy. -Peginterferon alfa/ribavirin-experienced: Patients who have failed therapy with peginterferon alfa plus ribavirin -Baseline NS5A polymorphisms: NS5A resistance-associated polymorphisms at amino acid positions 28, 30, 31, or 93. -Peginterferon alfa/ribavirin/HCV protease inhibitor-experienced: Patients who have failed therapy with peginterferon alfa plus ribavirin plus HCV NS3/4A protease inhibitor (e.g., boceprevir, simeprevir, telaprevir) -Optimal regimen and duration of therapy not established for peginterferon alfa/ribavirin/HCV protease inhibitor-experienced genotype 1a-infected patients with at least 1 baseline NS5A resistance-associated polymorphism at positions 28, 30, 31, and 93. -The manufacturer product information for ribavirin tablets should be consulted regarding dosing and dose adjustments (if applicable). Use: For the treatment of chronic HCV genotype 1 or 4 infection
Warnings
You should not use Zepatier if you have moderate or severe liver disease.
Serious drug interactions can occur when certain medicines are used together with elbasvir and grazoprevir. Tell each of your healthcare providers about all medicines you use now, and any medicine you start or stop using.
If you've ever had hepatitis B, using Zepatier can cause this virus to become active or get worse. Tell your doctor if you don't feel well and you have right-sided upper stomach pain, vomiting, loss of appetite, or yellowing of your skin or eyes.
What other drugs will affect Zepatier
When you start or stop taking Zepatier, your doctor may need to adjust the doses of any other medicines you take on a regular basis.
Many drugs can interact with elbasvir and grazoprevir, and some drugs should not be used at the same time. Tell your doctor about all your current medicines and any medicine you start or stop using. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed here.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions